BlackRock
AGN.PRA

BlackRock’s Allergan plc AGN.PRA Stock Holding History

BlackRock’s Portfolio AGN.PRA Stock Details AGN.PRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-548,953
Closed -$322M – 5085
2017
Q4 		$322M Sell
548,953
-723
-0.1% -$467K 0.02% 1018
2017
Q3 		$406M Buy
549,676
+11,786
+2% +$9.78M 0.02% 792
2017
Q2 		$467M Sell
537,890
-106,564
-17% -$89.3M 0.02% 686
2017
Q1 		$547M Buy
644,454
+641,769
+23,902% +$532M 0.03% 604
2016
Q4 		$2.05M Sell
2,685
-89
-3% -$67.3K ﹤0.01% 1225
2016
Q3 		$2.28M Sell
2,774
-163
-6% -$141K ﹤0.01% 1151
2016
Q2 		$2.45M Sell
2,937
-1,182
-29% -$987K ﹤0.01% 1079
2016
Q1 		$3.79M Hold
4,119
– – 0.01% 916
2015
Q4 		$4.24M Buy
4,119
+60
+1% +$60.3K 0.01% 885
2015
Q3 		$3.83M Buy
+4,059
New +$4.23M 0.01% 853

Other funds holding AGN.PRA

PWS
Peloton Wealth Strategists Indianapolis, Indiana $271M AUM 19.14% 1-Year Est. Return

BlackRock's AGN.PRA Position: Q1 2018 in Review

BlackRock sold out of Allergan plc (AGN.PRA) in Q1 2018, closing a stake of 548,953 shares — an estimated $322M sold.

BlackRock first reported a position in AGN.PRA in Q3 2015 and held it in 10 quarters. The position peaked at $547M in Q1 2017. 1 fund tracked by Wall St. Rank holds AGN.PRA as of Q1 2018.

  • BlackRock reported no remaining Allergan plc position as of Q1 2018 after selling out during the quarter.
  • BlackRock sold 548,953 Allergan plc shares in Q1 2018, an estimated $322M.
  • BlackRock first reported a position in Allergan plc in Q3 2015 and held it in 10 quarters.
  • BlackRock's Allergan plc position peaked at $547M in Q1 2017.
  • 1 fund tracked by Wall St. Rank held Allergan plc as of Q1 2018.

Based on BlackRock's 13F filing for Q1 2018, filed 9 May 2018.